Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue$145.71M$145.71M+18.0% vs Q2 2022 Net Income$26.12M$26.12M+50.6% vs Q2 2022 EPS Diluted$0.49$0.49+48.5% vs Q2 2022 Gross Profit$72,738,000+14.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$54,923,000+1,851.1% Free Cash Flowderived$45,869,000N/M Margins · derivedGross margin49.9%−1.4 pt vs Q2 2022
Operating margin25.3%+5.2 pt vs Q2 2022
Net margin17.9%+3.9 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end